摘要
目的:探讨早期强化他汀治疗对急性冠脉综合征(ACS)患者血清中基质金属蛋白酶8(MMP-8)和组织抑制因子1(TIMP-1)水平的影响。方法:ACS患者148例,随机分为常规他汀组(阿托伐他汀20 mg/d)和强化他汀组(阿托伐他汀40mg/d),治疗1月后观察两组治疗前后MMP-8和TIMP-1水平的变化。结果:两组治疗后血清中MMP-8均下降,强化组下降明显(P<0.05),而TIMP-1均有升高,强化组上升显著(P<0.05)。结论:早期大剂量应用阿托伐他汀治疗可降低ACS患者血清MMP-8水平和升高TIMP-1水平,抑制炎性反应,促进斑块的稳定。
Objective: To explore the effect of intensive atorvastatin therapy on serum levels of matrix metalloproteinase- 8 (MMP- 8) and tissue inhibitor of metalloproteinase- 1 (TIMP- 1 ) in patients with acute coronary syndrome(ACS). Methods: A total of 148 patients with ACS were randomly divided into intensive atorvastatin therapy group (74 cases) and moderate atorvastatin therapy group (74 cases). After treatment for 1 month, the serum levels of MMP-8 and TIMP-1 were measured by enzyme-linked immunosorbent assay (ELISA) and analyzed. Results: The serum levels of MMP-8 were significantly decreased in two groups compared with pro-treatment, serum levels of TIMP-1 in the two groups were significantly higher than that of pro-treatment, but it was significantly higher in intensive:atorvastatin group than that of atorvastatin group(P〈0.05). Conclusion: The effect of intensive atorvastatin therapy on serum levels of MMP-8 and TIMP-1 in patients with ACS contributes to suppression of inflammation response, matrix degradation, and the stability of atherosclerosis plaque.
出处
《西北国防医学杂志》
CAS
2014年第6期512-514,共3页
Medical Journal of National Defending Forces in Northwest China
关键词
急性冠脉综合征
强化他汀治疗
基质金属蛋白酶8
组织抑制因子1
Acute coronary syndrome
Intensive atorvastatin therapy
Matrix metalloproteinase- 8
Tissue inhibitor of metalloproteinase-1